Assessment of CD73 activity in breast cancer-derived small extracellular vesicles: application to monitoring of patients’ responses to immunotherapy
In breast cancer-derived sEV, as in melanoma-derived sEV, CD73 is the gateway enzyme regulating ADO formation from upstream AMP. The quantitation in sEV of N<sup>6</sup>-etheno-AMP conversion to N<sup>6</sup>-etheno-ADO ± neutralizing anti-CD73 antibodies provides a measure of the ability of these antibodies to suppress ADO production and could potentially serve as a personalized predictor of CD73 activity in patients with cancer.
Authors
- Edwin K. Jackson (ORCID: https://orcid.org/0000-0002-8101-6009)
- Cynthia Timmers (ORCID: https://orcid.org/0000-0002-0509-0805)
- Manti Guha (ORCID: https://orcid.org/0000-0003-1576-3580)
- T Chadderton
- Theresa L. Whiteside (ORCID: https://orcid.org/0000-0001-7316-6181)
- Matthew C. Stubbs (ORCID: https://orcid.org/0000-0003-3771-7083)
- Sarita Sehra
Institutions
- University of Pittsburgh (US)
- Incyte (United States) (US)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2025-03-22
- DOI
- https://doi.org/10.1016/j.iotech.2025.101052
- Citations
- 1
- Primary Topic
- Extracellular vesicles in disease
- Type
- article
- Field-Weighted Citation Impact
- 0.81